Prostat biyopsisi yapılan hastalarda Gleason gruplarının tahmininde nötrofil/ lenfosit oranının önemi

Amaç: Biz bu çalışmada lokalize prostat kanserlerinde Gleason gruplarına göre, N/L oranları arasında önemli bir fark olup olmadığını araştırmayı amaçladık. Gereç ve Yöntemler: Transrektal ultrason eşliğinde prostat biyopsisi yapılan ve patoloji sonucu prostat kanseri gelen hastalar retrospektif olarak incelendi. Tüm hastaların nötrofil/lenfosit oranları belirlendi. Yaşları, PSA değerleri ve vücut kitle indeksleri (BMI) kaydedildi. Hastalar ISUP 2014 tanımlamasına göre 5 gleason grubuna ayrıldı. Grupların N/L oranları ve diğer demografik verileri birbirleri ile karşılaştırıldı. Bulgular: Çalışma kriterlerine uyan 86 hastanın verileri kaydedildi. Grupların N/L oranları birbirleri ile karşılaştırıldığında Grup 1’de 2.13 (0.27-9.28), grup 2’de 2.22 (0.27-1.52), grup 3’de 2.40 (1.41-6.30), grup 4’de 1.90 (0.91-2.99) ve grup 5’de 2.11 (0.273.62) olarak saptandı (p=0.74). Sonuç: Çalışmamıza göre N/L oranının tüm Gleason gruplarında benzer olduğu saptanmıştır. N/L oranının lokalize PCa hastalarında prognostik bir faktör olup olmadığını saptamak için geniş hasta serili prospektif çalışmalara ihtiyaç vardır.

Emphasis of neutrophil to lymphocyte for prediction of Gleason groups in patient who underwent prostate biopsy

Aim: In this study we aimed to determine the status of the neutrophil lymphocyte ratios of the new ISUP Gleason groups. Material and Methods: Patients who underwent transrectal ultrasound-guided prostate biopsy and who had pathologically proven prostate cancer were evaluated retrospectively. Neutrophil / lymphocyte ratios of all patients were determined. Their age, PSA values and body mass index (BMI) were recorded. Patients were assigned to 5 Gleason groups according to ISUP 2014 definition. N / L ratios and other demographic data of the groups were compared with each other. Results: Data from 86 patients meeting the study criteria were recorded. N/L ratios were found as 2.13 (0.27-9.28) in group 1, 2.22 (0.27-1.52) in group 2, 2.40 (1.41-6.30) in group 3, 1.90 (0.91-2.99) in group 4 and 2.11 (0.27-3.62) in group 5 (p=0.74). Conclusion: N / L ratio was found to be similar in all Gleason groups according to present study. Prospective studies with large patient populations are needed to determine whether N / L ratio is a prognostic factor in localized PCa patients or not.

Kaynakça

Ceylan Y, Günlüsoy B, Degirmenci T et al. Neutrophil-tolymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-biopsy in patients with a previous benign pathology and consistently 2.5-10 ng/ml PSA value. Arch Esp Urol 2016;69:627-635.

Gokce MI, Tangal S, Hamidi N, Suer E, Ibis MA, Beduk Y. Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance. Can Urol Assoc J 2016;10:383-387.

Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006;164:1094-1102.

Bebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007;109:875-81.

Xiang YZ, Xiong H, Cui ZL et al.The association between metabolic syndrome and the risk of prostate cancer, highgrade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res 2013;32:9.

Nind AP, Nairn RC, Rolland JM. Lymphocyte anergy in patients with carcinoma. Br J Cancer 1973;28:108-117.

Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy Ann N Y Acad Sci 2013;1284:1-5.

Naito H, Sugimoto M, Taketa S, Kakehi Y. Clinical significance of neutrophil-to-lymphocyte ratio in patients with prostate cancer. Hinyokika Kiyo 2017;63:63-67.

Uemura K, Kawahara T, Yamashita D et al. Neutrophil-toLymphocyte ratio predicts prognosis in castration-resistant prostate cancer patients who received cabazitaxel chemotherapy. Biomed Res Int 2017;2017:7538647.

Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G. Glaskow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer 2013;11:423-30.

Minardi D, Scartozzi M, Montesi L et al. Neuyrophil-tolymphocyte ratio may be associated with the outcome in patient with prostate cancer. Springerplus 2015;4:255.

Pei XQ, He DL, Tian G et al. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-lymphocyte ratio in patients from Northwestern China. Int Urol Nephrol 2017;49:629-35.

Boegemann M, Schlack K, Thomes S et al. The role of neutrophil to lymphocyte ratio for survival outcomes in patients with metastatic castration-resistant prostate cancer treated with abiraterone. Int J Mol Sci 2017;18.

Templeton AJ, Pezaro C, Omlin A et al. Simple prognostic score for metastatic castration –resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014;120:3346-52.

Ceylan C, Camtosun A, Doluoglu OG et al. Emphasis of neutrophil-to-lymphocyte ratio in non-metastatic renal cell carcinoma. Urologia. 2014 Jan-Mar;81:51-6. doi: 10.5301/ urologia.5000032.

Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. Br Med J Open 2015;5:e006404.

D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.

Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specifi cantigen test: a review of current evidence. JAMA 2014 Mar 19;311:1143-9.doi: 10.1001/ jama.2014.2085. Review. PubMed PMID: 24643604.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013 Jan 31;CD004720. doi:10.1002/14651858.CD004720.pub3.

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. GradingCommittee. The 2014 International Society of Urological Pathology (ISUP)Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40:244-52. doi: 10.1097/ PAS.0000000000000530.

Ozcan C, Telli O, Ozturk E et al. The prognostic significance of preoperative leukocytosis and neutrophil-to-lymphocyte ratio in patients who underwent radical cystectomy for bladder cancer. Can Urol Assoc J 2015;9 (11-12):E789-94.

Templeton AJ, McNamara MG, Seruga B et al. Prognostic role of neutrophil to lymphocyte ratio in solid tumours: A systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124. doi: 10.1093/jnci/dju124.

Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.

Partin AW, Mongold LA, Lamm DM et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-8.

Hessels D, Klein Gunnewiek JMT, van Oort I et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44:8-16.

Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 2014; 6:74-7.

Bryant RJ, Sjoberg DD, Vickers AJ et al. Predicting highgrade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst 2015;107. pii: djv095.

Stephan C, Lein M, Junk K et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997;79:104-9.

Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.

Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20.

Stamey TA, Yang N, Hay AR, Mc Neal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916.

Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care 2013; 51: 295-300.

Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136: E359-86.

Kaynak Göster

Yeni Üroloji Dergisi
  • ISSN: 1305-2489
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2005

43131

Sayıdaki Diğer Makaleler

Our mid-term follow-up results in bladder tumors below 40 years of age

Fatih URUÇ, Serkan AKAN, BEKİR ARAS, Özgür Haki YÜKSEL, Aytaç ŞAHİN, Ayhan VERİT

Epididim kistini taklit eden skrotal agresif anjiomiksoma: Olgu sunumu

Ömer Faruk YAĞLI, Serkan ÖZCAN

Synchronous prostate and renal cancer: A series of two cases

FATİH AKDEMİR, Önder KAYIGİL, EMRAH OKULU

Kas invaziv mesane kanseri nedeniyle radikal sistektomi yapılan hastalarda hasta yaşının onkolojik ve sağkalım sonuçları üzerine etkisi

Ertuğrul ŞEFİK, Serdar ÇELİK, İsmail BASMACI, BÜLENT GÜNLÜSOY, Serkan YARIMOĞLU, Tarık YONGUÇ, İBRAHİM HALİL BOZKURT, Çetin DİNÇEL

Ureteral injury during robotic-assisted laparoscopic radical prostatectomy: Case report

Abdullah Hızır YAVUZSAN, Selçuk ŞAHİN, Taner KARGI, İsmail YİĞİTBAŞI, Volkan TUĞCU

Renal hücreli karsinom testis metastazı: Olgu sunumu

İLKE ONUR KAZAZ, FATİH ÇOLAK, Ayhan ARSLAN, SEVDEGÜL AYDIN MUNGAN, Elanur KAHRAMAN, ERSAGUN KARAGÜZEL

Güncel bilgiler ışığında her yönüyle sünnet

Osman AKYÜZ, Soner COBAN, Mehmet Nuri BODAKÇI, Mehmet DEMİR, ABDURRAHMAN AVAR ÖZDEMİR

Efficacy of Optical Internal Urethrotomy with Intermittent Self Dilatation for Urethral Stricture: A Randomized Prospective Study

Ekrem AKDENİZ, Mustafa Suat BOLAT

Selection of anesthesia to reduce anxiety, worry and fear in male circumcision

Muhammet GUZELSOY, Ali Rıza TÜRKOĞLU, Serpil SANCAR, Soner COBAN, Dursun ÜNAL, MURAT ÖZTÜRK, Halil GÜZELSOY, HAKAN DEMİRCİ

Elektif erkek sünneti; Medikolegal tartışmalar ve güncel literatür

Zeki BAYRAKTAR